アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
To produce this antibody the recombinant Rev (strain BRU) has been used as immunogen. The peptide sequences were not derived from particular strains of HIV1, but were designed as (artificial) B-clade (strain) consensus sequences. Sequences in Swiss prot belong to particular HIV1 strains. For epitope mapping synthetic peptides were used.
Our Abpromise guarantee covers the use of ab25871 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500. Predicted molecular weight: 13 kDa.|
|Radioimmunoprecipitation||Use at an assay dependent dilution.|
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"